跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
Approvals
/
Health Canada
/
EMPAVELI
Authorized
STANDARD
EMPAVELI
Swedish Orphan Biovitrum AB (Publ)
🇨🇦 Health Canada
Approval Date
Jul 4, 2025
Approval ID
3ed33292607200a0
Company
Swedish Orphan Biovitrum AB (Publ)
Type
Standard
Approval Details
Approval Id
3ed33292607200a0
Drug Approval Canada Name
EMPAVELI
Product Name
EMPAVELI
Status
Marketed
Status Date
2023-02-15
Original Market Date
2023-02-15
Din
02533294
Drug Class
Human
Dosage Form
Solution
Route Of Administration
Subcutaneous
Schedule
Prescription
Ahfs
90:20.00
Atc Original
L04AJ03 PEGCETACOPLAN
Atc Name
l 04 aj 03
Aig Number
0164341001
Company Name
Swedish Orphan Biovitrum AB (Publ)
Company Address
Tomtebodav 23a, Stockholm, --, Sweden, 11276
Company Detail Path
/organization/swedish-orphan-biovitrum-ab-publ
Company Information
Pharmaceutical Company Name
Swedish Orphan Biovitrum AB (publ)
Name En
Swedish Orphan Biovitrum AB (publ)
Name Zh
索比制药
Country Name
Sweden
Province Name
stockholm,country_se
City Name
solna,stockholm,country_se
Address
Tomtebodavägen 23A
Website
https://www.sobi.com
Description
International biopharmaceutical company focused on rare diseases in haematology, immunology and specialty care; operates in around 30 countries with headquarters in Stockholm. Listed on Nasdaq Stockholm (SOBI).
Active Ingredients
PEGCETACOPLAN
1080 MG / 20 ML
Authorized
Quick Info
Agency
Health Canada
Country
🇨🇦
Approval Date
Jul 4, 2025
Approval ID
3ed33292607200a0
Type
Standard
Back to Health Canada Approvals